Merck Wins 2 Big Approvals, a Surprise from Old ‘Dex,’ and a Digital Therapeutics First

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Illumina’s Bet on Early Cancer Detection & ESMO Highlights
Moderna and Pfizer’s Vaccine Transparency, Gilead’s Megadeal and a Tribute to Bill Sr.
Industry and Academia Take a Stand for Science
FDA and CDC Credibility Tarnished; Pfizer Sprints Ahead With COVID19 Vaccine